Screener
Avalo Therapeutics AVTX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's total costs & expenses?
- Avalo Therapeutics (AVTX) reported total costs & expenses of $31.52M in Q2 2026.
- How has Avalo Therapeutics's total costs & expenses changed year-over-year?
- Avalo Therapeutics's total costs & expenses increased by 63.2% year-over-year, from $19.32M to $31.52M.
- What is the long-term trend for Avalo Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Avalo Therapeutics's total costs & expenses has grown at a -4.4% compound annual growth rate (CAGR), from $87.53M to $72.98M.
- What does total costs & expenses mean?
- The aggregate sum of all operating and non-operating costs incurred by the company to sustain its business operations, including research, development, and administrative functions. This metric serves as a primary indicator of the company's overall burn rate and operational scale. It is essential for evaluating the company's cost structure and the efficiency with which it manages resources to achieve clinical milestones.
Ask your AI about Avalo Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude